Page 105 - CIBEREHD2016-ENG

Most relevant scientific articles
• Jauregui-Amezaga A., Rovira M., Marin P., Salas A., Pino-Donnay S., Feu F. et al. Improving safety of autologous haematopoietic stem cell transplantation in patients with Crohn’s disease. Gut. 2016.
• Danese S., Fiocchi C., Panes J.. Drug development in IBD: From novel target identification to early clinical trials. Gut. 2016.
• Mora-Buch R., Dotti I., Planell N., Calderon-Gomez E., Jung P., Masamunt M.C. et al. Epithelial IL-1R2 acts as a homeostatic regulator during remission of ulcerative colitis. Mucosal Immunology. 2016;9(4):950-959.
• Panes J., Garcia-Olmo D., Van Assche G., Colombel J.F., Reinisch W., Baumgart D.C. et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: A phase 3 randomised, double-blind controlled trial. The Lancet. 2016.
• Dotti I., Mora-Buch R., Ferrer-Picon E., Planell N., Jung P., Masamunt M.C. et al. Alterations in the epithelial stem cell compartment could contribute to permanent changes in the mucosa of patients with ulcerative colitis. Gut. 2016.
Hightlights
The inflammatory bowel disease Group at Hospital Clínic de Barcelona has continued the development of an active program of cell therapy. It is now the groups with the largest experience in autologous hematopoietic stem cell transplant for the treatment of refractory Crohn’s disease worldwide, and we have provided significant contributions to the field that increase the safety of the procedure without compromising efficacy. We have also had a significant contribution in collaboration with the industry
in the development of Mesenchymal stem cell therapy for treatment fo perianal fistulizing disease. This innovative therapeutic approach affords closure of fistula to patients that previously failed all available medical options.
Our group has also provided new insights into inflammatory bowel disease pathogenesis based on the use of organoids. We have shown that permanent changes in the colonic epithelium of patients with ulcerative colitis can be promoted by alterations imprinted in the intestinal stem cell compartment. These changes may contribute to perpetuation of the disease.
Significant contributions to optimization of clinical practice include the participation in the development of the European Crohn’s and Colitis guideline on the use of biosimilars in inflammatory bowel disease, as well as in consensus documents on the assessment of disease severity and outcomes over time.
EHD
research Groups 105